Download PDF
Thromb Haemost 1981; 46(02): 550-553
DOI: 10.1055/s-0038-1653408
Original Article
Schattauer GmbH Stuttgart

Effects of Suloctidil on Platelet Survival Time Following Cardiac Valve Replacement

Chr Col-de Beys
The Department of Haematology, Haemostasis Unit, University of Louvain, Brussels, Belgium
,
A Ferrant
The Department of Haematology, Haemostasis Unit, University of Louvain, Brussels, Belgium
,
M Moriau
The Department of Haematology, Haemostasis Unit, University of Louvain, Brussels, Belgium
› Author Affiliations
Further Information

Publication History

Received 12 January 1981

Accepted 02 July 1981

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Platelet functions and blood clotting parameters were examined in 23 patients with a shortened platelet survival time after cardiac valve replacement.

Treatment was given at random: for a first group antivitamins K with suloctidil and for the second group antivitamin K alone.

Six weeks of treatment with antivitamin K alone did not induce any significant change in the platelet survival time, platelet retention or platelet factor 4 in plasma.

In contrast, the shortened platelet survival time increased significantly after 6 weeks of treatment with suloctidil. Moreover the platelet retention and the amount of platelet factor 4 in plasma were significantly reduced, indicating that normalization of platelet survival is the result of decreased destruction, presumably at the level of the prosthetic surface. The clinical benefits expected from these results remain to be validated by a longer follow up period.

Keywords

Suloctidil - Cardiac valve replacement - Platelet survival time
 

  • References

  • 1 Starr A, Grunkemeier G, Lambert L, Okies JE, Thomas D. Mitral valve replacement. A 10 year follow-up of non cloth-covered vs cloth-covered caged-ball prostheses Circulation 1976; 54 suppl (Suppl. 03) 47-56
    CrossrefPubMedGoogle Scholar
  • 2 Roberts WC, Hammer WJ. Cardiac pathology after valve replacement with a tilting disc prostesis (Björk-Shiley Type). A study of 46 necropsy patients and 49 Björk-Shiley prostheses Am J Cardiol 1976; 37: 1024-1033
    CrossrefPubMedGoogle Scholar
  • 3 Cohn LH, Mudge GH, Pratter F, Collins JJ. Five to eight year follow-up of patients undergoing porcine heart-valve replacement. N Engl J Med 1981; 304: 258-262
    CrossrefPubMedGoogle Scholar
  • 4 Bamhorst DA, Oxman HA, Connolly DC. Isolated replacement of the mitral valve with the Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 1976; 71: 230-237
    PubMedGoogle Scholar
  • 5 Bamhorst DA, Oxman HA, Connolly DC. Long term follow-up of isolated replacement of the aortic and mitral valve with the StarrEdwards prosthesis. Am J Cardiol 1975; 35: 228-233
    CrossrefPubMedGoogle Scholar
  • 6 Taguchi K, Matsumara H, Washizu T, Hirao M, Kato K, Kato E, Mochizvki T, Takamura K, Mashimo I, Morifuji K, Nakagak M, Juma T. Effect of athrombogenic therapy, especially high dose therapy of Dipyridamole after prosthetic valve replacement. J Cardiovasc Surg 1975; 16: 8-15
    PubMedGoogle Scholar
  • 7 Steele P, Weily H, Davies H, Pappas G, Genton E. Platelet survival time following aortic valve replacement. Circulation 1975; 51: 358-362
    CrossrefPubMedGoogle Scholar
  • 8 Sutton MG, Miller GA H, Oldershaw PJ, Paneth M. Anticoagulants and the Björk-Shiley prosthesis. Experience of 390 patients Br Heart J 1978; 40: 558-562
    CrossrefPubMedGoogle Scholar
  • 9 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
    CrossrefPubMedGoogle Scholar
  • 10 Weily H, Steele P, Davies H. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
    CrossrefPubMedGoogle Scholar
  • 11 Sullivan JM, Harken DE, Gorlen R. Pharmacologic control of thromboembolic complications of cardiac valve replacement. N Engl J Med 1971; 284: 1391-1394
    CrossrefPubMedGoogle Scholar
  • 12 Dale Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ballvalve prostheses. Am Heart J 1975; 89: 613-618
    CrossrefPubMedGoogle Scholar
  • 13 Weily H, Genton E. Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy Circulation 1970; 42: 967-972
    CrossrefPubMedGoogle Scholar
  • 14 Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves. Relationship of clinical effectiveness to alteration of platelet survival time Circulation 1979; 60: 910-913
    CrossrefPubMedGoogle Scholar
  • 15 Roba J, Bourgain R, Andries R, Claeys M, Van Opstal M, Lambelin G. Antagonism by suloctidil of arterial thrombus formation in rats. Thromb Res 1976; 9: 585-594
    CrossrefPubMedGoogle Scholar
  • 16 De Gaetano G, Miragliotta G, Roncucci R, Lansen J, Lambelin G. Suloctidil: a novel inhibitor of platelet aggregation in human beings. Thromb Res 1976; 8: 361-371
    CrossrefPubMedGoogle Scholar
  • 17 Gurewich V, Lipinski B. Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thromb Res 1976; 9: 101-108
    CrossrefPubMedGoogle Scholar
  • 18 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-855
    CrossrefPubMedGoogle Scholar
  • 19 Bowie EJ W, Owen OH A, Thompson JH, Didsheim P. A test of platelet adhesiveness. Mayo Clin Proc 1969; 44: 306-308
    PubMedGoogle Scholar
  • 20 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 21 Hurlet-Birk JensenA, Legrand-Monsieur A, Masure R. Analysis of heparin neutralizing assay conditions. Thromb Res 1978; 13: 609-614
    CrossrefPubMedGoogle Scholar
  • 22 Vermylen C, Verstraete M. A simple method for the assay of factor VIII using 25 microliters of capillary blood. Br J Haemat 1968; a 14: 241-245
    CrossrefPubMedGoogle Scholar
  • 23 Laurell CB. Antigen antibody crossed electrophoresis. Ann Biochem 1965; 10: 358-361
    CrossrefPubMedGoogle Scholar
  • 24 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Path 1958; 2: 405-410
    PubMedGoogle Scholar
  • 25 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human betathromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
    CrossrefPubMedGoogle Scholar
  • 26 Okuno T, Crockatt D. Platelet factor 4 activity and thrombo-embolic episodes. Am J Clin Pathol 1977; 67: 351-355
    CrossrefPubMedGoogle Scholar
  • 27 Verhaeghe R, Vanhoof A. The concomitant use of suloctidil and a long acting oral anticoagulant. Acta Clin Bel 1977; 32: 36-38
    PubMedGoogle Scholar